KPTI - Karyopharm Therapeutics GAAP EPS of -$0.62 misses by $0.01 revenue of $39.68M beats by $3.72M
- Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q2 GAAP EPS of -$0.62 misses by $0.01 .
- Revenue of $39.68M (+75.6% Y/Y) beats by $3.72M .
- XPOVIO (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021
For further details see:
Karyopharm Therapeutics GAAP EPS of -$0.62 misses by $0.01, revenue of $39.68M beats by $3.72M